This revision description makes explicit that “GPR35 downregulation” leads to the inactivation of the AKT/HIF-1α signaling pathway, which in turn produces two synergistic anti-tumor outcomes: inhibition of proliferation and promotion of apoptosis (58). The gene discussed is AKT1; the disease is neoplasm.